Anthropic’s record IPO puts its science ambitions under scrutiny
Anthropic has completed the largest initial public offering on record, reaching a valuation of around US$1.5 trillion as it expands its scientific research efforts. The company behind Claude is pursuing drug discovery, protein design and mathematics, alongside ambitious charitable commitments. Its founders have pledged to donate 80% of their equity to charity, while the Anthropic Public Benefit Fund has an initial commitment of 5% of Anthropic’s shares.
The company has opened its first life sciences laboratory, announced pharmaceutical partnerships and begun pursuing its own drug leads. Chief executive Dario Amodei’s predictions that AI could rapidly overcome cancer and other complex diseases have drawn criticism from researchers and entrepreneurs who consider the timelines unrealistic.
Anthropic’s biological research has received a mixed reception. Researchers questioned the novelty of a proposed CRISPR-like system and the lack of experiments establishing its function. Claude Science, an agentic system connected to biological tools and databases, also generated binders against 15 protein targets. Computational biologist Anthony Gitter welcomed the company’s transparency about its prompts and generated sequences, despite broader disappointment with the initial results.
In mathematics, Anthropic collaborators solved a special case of the Navier-Stokes equations and are investigating foundations of the standard model of particle physics. Rigorous proofs provide a testing ground for reasoning models. Separately, researchers warn that pursuing superintelligent systems poses serious risks; Anthropic says safety research directly shapes model design, training and deployment.